What does altered hepatic parenchymal echogenicity mean?
Liver parenchymal echogenicity changes generally refer to pathological conditions related to liver function.
Changes in liver parenchymal echogenicity are an imaging manifestation of alterations in liver density and tissue characteristics, commonly appearing in the early stages of chronic hepatitis or hepatic fibrosis. Such changes include uneven distribution of echogenicity, coarsened and enhanced liver echoes, and are frequently observed in chronic hepatitis. The severity of chronic hepatitis should be assessed comprehensively based on liver function tests, albumin levels, coagulation function, and other clinical factors. However, most cases of chronic hepatitis are not severe unless they have progressed to cirrhosis. Early-stage liver cancer is generally not very serious and can often be cured, with little impact on five-year survival rates.
For patients with liver parenchymal echogenicity changes, close monitoring of liver function and hepatoprotective treatment are required. It is advisable to follow medical advice in using liver-protecting and enzyme-lowering medications such as bifendate tablets, compound glycyrrhizin tablets, or polyene phosphatidylcholine tablets. For hepatitis-related cirrhosis, oral antiviral therapy is necessary, including drugs like entecavir, telbivudine, or adefovir dipivoxil, which usually require lifelong administration.
Patients who are found to have liver parenchymal echogenicity changes should undergo comprehensive evaluations under medical guidance and actively pursue targeted treatments addressing the underlying cause.